A team of researchers has developed microparticles capable of carrying three different molecules on three different docks, or "patches." They could eventually provide a one-two-three punch against cancer, the researchers say.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a light-activated delivery system for chemotherapy.
Miltenyi Biotec said today that the FDA had approved its device for humanitarian use in patients with acute myeloid leukemia (AML) who are getting allogeneic stem cell transplants from matched, related donors. The device, called the CliniMACS CD34 Reagent System, is designed to lower the risk of graft-versus-host disease (GVHD), which is a common complication of this type of transplant.
Researchers have found that gravity and electrostatics are two important factors at play between cell membranes and drug reservoirs. With these new findings, the scientists hope to create systems that deliver cancer drugs slowly and continuously.
Microlin Bio a fledgling diagnostic and drug developer, filed plans to raise as much as $25 million in a modest initial public offering designed to advance work on tests and related therapies for four different kinds of cancers.
Like any moving target, cancer that has metastasized is notoriously difficult to treat. One of the major hurdles in cancer research is the detection of cancer cells that have spread in the body, but researchers at Cornell have developed a compound that could piggyback on white blood cells and deliver cancer-killing drugs very effectively.
In its new, $15 million round of late-stage financing, metabolomics-focused Metabolon has added Camden Partners and Sumitomo to its list of investors.
Two birds with one stone? How about two drug targets with one delivery vehicle? Researchers in North Carolina have developed a single nanoparticle capable of carrying two separate drugs to two different locations in a cancer cell. The aim is to program the delivery in such a way that maximizes the efficiency of each drug.
In what could become a vast improvement to the delivery of gene therapy within the body, U.S. researchers have developed injectable DNA-carrying viruses that could eventually stop tumor growth or make chemotherapy more effective.
Royal Philips on Thursday announced it is the first medical device company to win 510(k) clearance from the FDA for an application to measure breast density as part of routine mammograms. Women with dense breasts--i.e., less fatty tissue--may be at much higher risk of breast cancer.